CRBPCorbus Pharmaceuticals Inc.Signing up patients
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Solid Tumor, Adult
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 348 (planned)
- Started
- Apr 1, 2024
- Main results expected
- Jan 16, 2027
- Fully finished
- Jan 27, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: To confirm the safety and tolerability and determine MTD and PADR for CRB-701
Measured over: 21 days
Part B & C: To evaluate efficacy in terms of Objective Response Rate (ORR)
Measured over: Up to 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06265727 · record last updated 2026-01-08 · checked 2026-11-09 15:47 UTC